Promoting Health through Skin with Abrax

Promoting Health Through Skin

Harnessing the Potential of Unrecognized Power of Skin-Derived Factors

Who We Are

A Breakthrough in Skin Treatment

A Topical Medication for Weight Management

Abrax is creating a future where people can live healthier lives through the development of groundbreaking therapies that address skin and lipid disorders.

More Details

News

Our Updates

Others

Abrax Japan’s Revolutionary Obesity Treatment F-275 Featured on Nippon Television with Dr. Kambayashi

2025.03.09

Press Release

Abrax Japan Appoints Dr. William Chin and Dr. Zoltan Arany to its Scientific Advisory Board

2025.02.15

Press Release

Abrax Japan Announces Innovative Approach to Stimulate Weight Loss and Seek FDA Approval for Lipid Disorders

2024.07.26

Press Release

Abrax Japan and Kyushu University Graduate School concluded Joint Research Agreement

2023.12.16

TSE Filings

Abrax Japan’s lead asset ABX was featured in an information program on the TBS network

2023.12.05

Others

Dr. Taku Kambayashi will appear on Nippon TV series “Learn with Kazu-Laser” on June 20, 2023.

2023.06.15

TSE Filings

Abrax Japan Announces Completion of IND-Enabling Safety Studies to Advance Lead Program towards Clinical Trials

2023.05.07

TSE Filings

Abrax Japan Announces License Agreement with the University of Pennsylvania

2022.04.21

TSE Filings

Dr. Kambayashi wins both competitions in STAT Madness 2022

2022.04.06

TSE Filings

Abrax Japan announces $3 million Seed 4 financing to support clinical development of ABX-919 for atopic dermatitis

2021.12.24

TSE Filings

Abrax Japan’s lead asset ABX was featured in an information program on the TBS network

2023.12.05

TSE Filings

Abrax Japan Announces Completion of IND-Enabling Safety Studies to Advance Lead Program towards Clinical Trials

2023.05.07

TSE Filings

Abrax Japan Announces License Agreement with the University of Pennsylvania

2022.04.21

TSE Filings

Dr. Kambayashi wins both competitions in STAT Madness 2022

2022.04.06

TSE Filings

Abrax Japan announces $3 million Seed 4 financing to support clinical development of ABX-919 for atopic dermatitis

2021.12.24

TSE Filings

Co-founder of Abrax Japan, Dr. Taku Kambayashi, publishes article in Science entitled “Thymic stromal lymphopoietin induces adipose loss through sebum hypersecretion”

2021.08.08

TSE Filings

Abrax Japan establishes a subsidiary company, Abrax Australia PTY LTD, in Australia.

2021.07.22

Press Release

Abrax Japan Appoints Dr. William Chin and Dr. Zoltan Arany to its Scientific Advisory Board

2025.02.15

Press Release

Abrax Japan Announces Innovative Approach to Stimulate Weight Loss and Seek FDA Approval for Lipid Disorders

2024.07.26

Press Release

Abrax Japan and Kyushu University Graduate School concluded Joint Research Agreement

2023.12.16

TSE Filings

Abrax Japan’s lead asset ABX was featured in an information program on the TBS network

2023.12.05

TSE Filings

Abrax Japan Announces Completion of IND-Enabling Safety Studies to Advance Lead Program towards Clinical Trials

2023.05.07

TSE Filings

Abrax Japan Announces License Agreement with the University of Pennsylvania

2022.04.21

TSE Filings

Dr. Kambayashi wins both competitions in STAT Madness 2022

2022.04.06

TSE Filings

Abrax Japan announces $3 million Seed 4 financing to support clinical development of ABX-919 for atopic dermatitis

2021.12.24

TSE Filings

Co-founder of Abrax Japan, Dr. Taku Kambayashi, publishes article in Science entitled “Thymic stromal lymphopoietin induces adipose loss through sebum hypersecretion”

2021.08.08

TSE Filings

Abrax Japan establishes a subsidiary company, Abrax Australia PTY LTD, in Australia.

2021.07.22

Others

Abrax Japan’s Revolutionary Obesity Treatment F-275 Featured on Nippon Television with Dr. Kambayashi

2025.03.09

Others

Dr. Taku Kambayashi will appear on Nippon TV series “Learn with Kazu-Laser” on June 20, 2023.

2023.06.15

TSE Filings

Abrax Japan Announces Completion of IND-Enabling Safety Studies to Advance Lead Program towards Clinical Trials

2023.05.07

TSE Filings

Abrax Japan Announces License Agreement with the University of Pennsylvania

2022.04.21

TSE Filings

Dr. Kambayashi wins both competitions in STAT Madness 2022

2022.04.06

TSE Filings

Abrax Japan announces $3 million Seed 4 financing to support clinical development of ABX-919 for atopic dermatitis

2021.12.24

TSE Filings

Co-founder of Abrax Japan, Dr. Taku Kambayashi, publishes article in Science entitled “Thymic stromal lymphopoietin induces adipose loss through sebum hypersecretion”

2021.08.08

TSE Filings

Abrax Japan establishes a subsidiary company, Abrax Australia PTY LTD, in Australia.

2021.07.22

Archive page

Contact

Your Inquiries

Careers

Join Us (Japanese site)

Investors

password required